Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Medtronic announces CE mark for recapturable CoreValve Evolut R System

Medtronic, Inc. today announced CE (Conformité Européene) Mark for the 23 mm CoreValve Evolut(TM) R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that  advance valve performance and deliverability during the procedure, while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new position either above or below its current placement) the valve during deployment phase, if needed.

Thumbnail

Heart failure patients with afib get little benefit from beta-blockers

Beta-blockers appeared to offer no or little clinical benefit to patients with heart failure and atrial fibrillation in a study presented at the European Society of Cardiology’s annual meeting and concurrently published online Sept. 2 in The Lancet.

ESC Hot Line: Data reports NVAF patients taking Pradaxa (dabigatran etexilate mesylate) experienced slower decline in kidney function compared to those on warfarin

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa (dabigatran etexilate mesylate) compared to warfarin. The findings suggest that patients treated with PRADAXA experienced a slower decline in kidney function compared to those being treated with warfarin, with the slower decline most marked in patients treated with PRADAXA who had mild kidney impairment at the start of the RE-LY trial. The results were presented today during the European Society of Cardiology (ESC) Congress 2014.

Thumbnail

TAVR: Raising the Bar to Achieve Good Outcomes

The FDA approved two types of devices for transcatheter aortic valve replacement (TAVR) after determining they were better than standard therapy for inoperable patients and an alternative to open surgery in high-risk patients. Nonetheless, this generally elderly patient population poses challenges and there are still potential missteps that could derail TAVR. Patient selection tools, 3D imaging and other approaches may minimize the likelihood of complications and poor outcomes occurring.

Thumbnail

CT-based Mobile Stroke Care

Germany's ground-breaking use of CT scanners in ambulances to assess for possible stroke inspired one program in Houston to follow suit. Supporters predict it will transform care in the future. 

Thumbnail

Carotid Artery Stenting: Making Progress Amid Reimbursement Purgatory

Overall periprocedural death and stroke rates have declined in patients undergoing carotid artery stenting (CAS). 

Global survey of cardiologists highlights complexity of managing non-valvular atrial fibrillation and reinforces need for individualized approach to patient care

Daiichi Sankyo and the Heart Rhythm Society today announced results from a global survey, which polled cardiologists from around the world and revealed that a majority (58%) of cardiologists agree that there is no such thing as a “typical” non-valvular atrial fibrillation (NVAF) patient.

Subgroup analysis of ENGAGE AF-TIMI 48 explores the relationship between edoxaban dose, concentration, anti-Factor Xa activity and outcomes

Daiichi Sankyo Company, Limited today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation (NVAF). The analysis also compared rates of major bleeding and efficacy outcomes [stroke and systemic embolic events (SEE)] of edoxaban versus warfarin, stratified by dose reduction status.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.